4D pharma plc: 4D Pharma to Participate in Upcoming Cantor Fitzgerald Microbiome Leaders Panel
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) a novel class of drug derived from the microbiome, today announces Duncan Peyton, Chief Executive Officer of 4D pharma, will participate in Cantor Fitzgerald s virtual panel, titled Microbiome Players with Guided Readouts in 2021, on Thursday, February 18, 2021 at 15:00 GMT (10:00 ET).
A webcast of the panel will be available via the Events section of the 4D pharma website at www.4dpharmaplc.com.
About 4D pharma
Founded in February 2014, 4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx, that rationall
4D pharma Joins Landmark Parkinson s Progression Markers Initiative A landmark study sponsored by The Michael J. Fox Foundation to better understand Parkinson s disease and accelerate the development of new treatments 4D pharma will play an important role as PPMI considers the microbiome as an area of focus Leeds, UK, December l8, 2020 , - 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces that it has joined the Parkinson s Progression Markers Initiative (PPMI) as an industry partner. PPMI is a landmark study sponsored by The Michael J. Fox Foundation to better understand Parkinson s disease and accelerate the development of new treatments.